Zogenix to Release First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 8

EMERYVILLE, Calif., May 01, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the three months ended March 31, 2019, after the market close, and will host a corporate update conference call and webcast on Wednesday, May 8, 2019, at 4:30 PM Eastern Time.

Conference Call DetailsWednesday, May 8, at 4:30 PM Eastern Time/1:30 PM Pacific Time

About ZogenixZogenix is a global pharmaceutical company committed to developing and commercializing transformative therapies to improve the lives of patients and their families living with rare diseases. The company’s MAA for its lead candidate FINTEPLA® (ZX008, fenfluramine) has been accepted for review by the European Medicines Agency and is in development in Japan. Zogenix is preparing for a Type A meeting with the U.S. Food & Drug Administration to discuss resubmission of the company’s NDA. For more information, visit www.zogenix.com.

CONTACTS:ZogenixMelinda BakerSenior Director, Corporate Communications[email protected]

MediaRachel LipsitzPublic Relations, Syneos Health +1 (858) 449 9575 | [email protected] 

Investors Andrew McDonaldFounding Partner, LifeSci Advisors LLC+1 (646) 597-6987 | [email protected]

You May Also Be Interested In

• Amphenol (APH) Tops Q1 EPS by 7c, offers guidance
• JPM sees risk of further negative earnings revisions for Tesla (TSLA)
• Capitol Federal Financial (CFFN) Misses Q2 EPS by 1c